Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPTL could be a bargain...
PPTL -- Premium Petroleum Corp.
Com ($0.0001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
REPEAT/Premium Petroleum, Inc. Initiates Seismic Program on its Boyne Lake Gas Prospect
CALGARY, Alberta, Oct 31, 2005 (BUSINESS WIRE) -- Premium Petroleum, Inc. (PINK SHEETS:PPTL) is pleased to announce that it has initiated its Seismic program on its Boyne Lake Gas Project. Due to the channel sand nature of the geology at the site, management has decided to shoot a seismic program to assist in identifying the optimum drill location on the subject lands. To this end, a highly respected geophysical firm of Petrel Robertson Consulting Ltd. has been retained to design, oversee, and interpret a 3-line 8 km seismic program. This program should be completed and interpreted within the next 30 to 60 days, subject to equipment availability.
"The power of seismic is that it raises the probability of success," commented Bruce Thomson, President and Chief Executive Officer of Premium Petroleum, Inc. "In this case from an estimated 35% to an over 70%," concluded Thomson.
About Premium Petroleum, Inc.
Premium is set to exploit petroleum and natural gas reserves in an environment of unprecedented commodity prices and under the guidance of a highly qualified management and technical team.
Premium is an emerging junior oil and gas company financially well connected, coupled with a strong management and technical team focused on exploiting oil and gas reserves in the Western Canadian Sedimentary basin to 6000 feet in depth. Management intends to pursue a growth strategy through Land Assembly, Joint Ventures (Farmin/Farmout), and Acquisitions. The Company has assembled a seasoned team of managers and technical professionals in the areas of geology, engineering, and legal (Petroleum Landman). With the depth of the management and technical team we have assembled, Premium is poised for aggressive asset growth and development.
For more detail about the company, its management, and projects, please refer to our web site: www.premiumpetroleum.com.
This news release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended; such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The Company may experience significant fluctuations in operating results due to a number of economic, competitive and other factors. These factors could cause operations to vary significantly from those in prior periods, and those projected in forward-looking statements. Information with respect to these factors, which could materially affect the Company and its operations, are included on certain forms the Company files with the Securities and Exchange Commission.
SOURCE: Premium Petroleum, Inc.
CONTACT: Premium Petroleum, Inc.
Bruce Thomson
(403) 264-2710
bruce@thomson.org
www.premiumpetroleum.com
Copyright Business Wire 2005
-0-
KEYWORD: United States
Canada
North America
New York
INDUSTRY KEYWORD: Energy
Oil/Gas
Bottom forming??
PDIV -- Premier Development & Investment, Inc.
Class A Com ($0.00002)(New)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Premier Announces September Players Grille Unit Same Store Sales Comps Increase 35%
TAMPA, Fla., Oct 18, 2005 (BUSINESS WIRE) -- Premier Development & Investment, Inc. (OTCBB:PDIV) announces that comparable same store restaurant sales at its wholly-owned Players Grille subsidiary increased 35.2% during the month of September 2005 compared with September 2004. Also, the number of customers, measured by overall check counts, increased 51.2% during September.
For the three-months ended March 31, 2005, June 30, 2005 and September 30, 2005, comparable same store restaurant sales increased 14.8%, 45.0% and 40.4%, respectively. For the same three-months ended check counts increased 20.1%, 55.2% and 58.1%, respectively.
Michael Hume, Players Grille's General Manager, stated, "We continued to generate strong sales growth for the month and three-months ended September 30, 2005. Furthermore, our trend of strong increases in sales of higher margin bottle beer, draft beer and liquor continued in the period. We fully expect this trend to continue as football and baseball seasons continues to unfold."
Premier Development & Investment, Inc. is a publicly held developer and operator of theme-based restaurant and bar concepts. These concepts are developed internally and through partnerships with other restaurant developers with the intent of building them into full-fledged chains and franchise opportunities. Premier owns and operates the Player's Grille Restaurant and Bar(TM), a casual dining sports themed concept based in Florida.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Premier Development & Investment, Inc.) contains statements that are forward-looking, such as statements relating to the future anticipated direction of the restaurant industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and prospective dealings and joint venture projects. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of Premier. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, domestic and global economic conditions, and changes in federal or state tax laws. For a description of additional risks and uncertainties, please refer to Premier's filings with the Securities and Exchange Commission.
SOURCE: Premier Development & Investment, Inc.
CONTACT: Premier Development & Investment, Inc., Tampa
Vicky Wright, 954-447-9268
ir@premierdev.com
http://www.premierdev.com
Copyright Business Wire 2005
INSQ...move to .04???
Radar INSQ for November/December ... the next 10-bagger
1. Q3 earnings release in 2 weeks where INSQ will report it's first
profit, and will report its termination of its $10 million Standby
Equity Distribution Agreement ("SEDA") with Cornell Capital Partners
(VERY BULLISH)
2. Closing of the IMS deal, will which will bring INSEQ to an
estimated $21 million in annualized revenue and $2.1 million in
EBITDA.
3. Closure to the Specialty Metal Manufacturer ("SMM") deal, which
is expected to add another $2 million in annualized revenue with
better than 10% EBITDA.
4. Launch of the secondary commodities exchange (GREX)
5. News due out regarding Tornado Generator (TAZ) being deployed in
New Orleans/Louisiana cleanup project
6. The restructuring of various debentures and the cancellation of
about 350 million shares of INSEQ common stock and warrants.
7. The Greenshift share conversion that will reduce the O/S by 3
billion shares.
8. Launch of the new Inseq Website scheduled for the 1st week of
December.
>>> TARGET PRICE = .04 over next 4-8 weeks <<<
Great Post on PBLS
PBLS @.03 Revenues up 300 %,$10 Mil. Stock Equity 1 Billion
Volume is up and Buying is heavy. Katrina and Rita has
Boosted revenues for Construction and Trucking Companys,
As well as Murphy and and Gravels Revenues, for Rebuilding
Of New Orleans and surrounding Areas.
Profit of $3 Million expected in 2005, Over $18,000,000 in
Revenues for 2006, with Billion Dollar in Mineral Reserves.
State of Wyoming oil lease has oil Reserves of approximately
5 million barrels of oil.At $52 a barrel= $260,000,000.00 Reserves
Currently Rome Oil & Gas Co. has 18 wells that are producing
between 5BBL/day to 50 BBL/day each, with an average of
26 BBL/day per well,selling oil at a PPB of $52-$57
18 x26 = 468 BBL/day $52 x 468 = $24,336 a day.
365 days x 24,336 = $8,882,640.00 annually Revenue
http://www.pbls.biz/pr43.htm Nov.03,2005 Press release
Both Oil Companys will add a minimum of $1,368,000.00 in revenues
for calendar year 2005, will generate over $12,000,000.00 in revenue
for the company in 2006.
http://www.pbls.biz/pr38.htm Sep 26, 2005 Press Release.
Murphy Sand & Gravel has proven mineral reserves of $300,000,000.
Should generate over $2,310,000.00 in revenues for the year 2005.
mining and sales capability at between $4 to $8 million per year
http://www.pbls.biz/msg.htm also http://www.pbls.biz/pr38.htm
PBLS anticipates $1,000,000,000 of mineral reserves end of 2006.
Heaslip Construction -Gross revenues will exceed $2,000,000.00 for
year 2005 .Ann Arbor Pools and Great Lakes Pool Plastering, should
bring in approximately $2,288,000.00 in revenues For 2005.
http://www.pbls.biz/pr38.htm Sep 26, 2005 Press release
Bayou State Trucking (BST) of Houma, Louisiana. is currently hauling
within the cities of New Orleans, Kenner, Belle Chasse, Chalmette,
Covington, Hammond, Lacombe and Slidell, Louisiana. Many of these
companies, including Durr Heavy Equipment and Construction Company,
count heavily on Bayou State Trucking (BST) of Houma, Louisiana.
Revenues to calendar year 2005 should be around $650,000.00.
http://www.pbls.biz/bst.htm , http://www.pbls.biz/pr38.htm
2004 Phoenix grossed $3,000,000 , 2005 Gross $10,000,000.00.
2006 Gross anticipated over $18,000,000.00 with mineral
reserves worth over $1,000,000,000.00 .
http://www.pbls.biz/pr38.htm Sep 26, 2005 Press release
PBLS has a total of 377,291,802 shares issued and outstanding as
of June 10, 2005, of which 228,085,575 are restricted shares,
and the remaining 149,206,227 shares are non-restricted shares
and considered to be the public "float" shares.
(PBLS) Released Unaudited Balance Sheet for 2004 on Aug 03, 2005 .
stockholders equity (net worth) of Phoenix is about $39.7 million.
Add The Oil Reserves another $60 Million . Making stockholders
Equity easily 90 Milliom.
http://www.pbls.biz/pr23.html June 14, 2005 Company Release.
NDOL....bigger than SPRL??? Opinions??
Tks for the greeting...let's make some money together :)
GLIF -- Grant Life Sciences, Inc.
+18% on Friday.
SSUF -- Sports Stuff.com, Inc.
Com ($0.001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Sports-Stuff.com Signs Three of the World's Top Poker Players
VANCOUVER, British Columbia, Nov 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- Sports-Stuff.com Inc. (OTC Pink Sheets: SSUF), a publisher and distributor of sports and entertainment for wide scale mobile platforms, today announced that that the Company has secured exclusive wireless rights with 3 of the top poker players in the world. Sports-Stuff.com will produce and publish voice ringtones, ringbacks, voicemail greetings and wireless web (WAP) sites featuring these players.
The Company owns exclusive wireless rights and will publish content for the following players:
Men "The Master" Nguyen: A living legend of poker, Men holds 6 World Series of Poker bracelets, is a three-time "Player of the Year" (1997, 2001, 2003) and has won more than 75 major tournaments.
David Williams: Dubbed "The Future of Poker" by Playboy Magazine, David was a runner-up at the 2004 World Series of Poker Main Event and runner-up in the World Poker Tour's Borgata Open.
Evelyn Ng: As well-known for her poker as her stunning looks and rising celebrity, Evelyn was a runner-up in the World Poker Tour's inaugural Ladies Invitational Tournament, and has a growing list of sponsorships and television appearances.
"Given the meteoric rise in the popularity of poker in the last few years, coupled with the growing demand for exciting wireless content, we felt that creating voice ringtones that featured the stars of the game was an excellent opportunity to capitalize on two growing markets," said Alex Murdoch, Director of Business Development for Sports-Stuff.com.
President Kevin Day commented: "Having such a talented group of players working closely with us is an exciting opportunity and we plan on taking full advantage of it by creating custom wireless web pages for these players so their many fans can keep up to date on tournament results, public appearances and the like."
The company expects to announce further signings with other top-caliber poker players in the coming weeks.
About SSUF
SSUF is a publisher and distributor of sports and entertainment related content for mobile platforms. The company's goal is to establish direct business relationships with wireless carriers, game developers, professional athletes, and data providers to deliver mobile video games, ring tones, mobile web sites and SMS alerts.
"SAFE HARBOR"
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE Sports-Stuff.com Inc.
CONTACT: Kevin Day of Sports-Stuff.com Inc., +1-866-815-2677, or
info@wireless-sports-stuff.com
URL: http://www.prnewswire.com
http://www.wireless-sports-stuff.com/
www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
-0-
Interesting Oil Play
KKPT -- KoKo Petroleum, Inc.
Com (No Par)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
KOKO Petroleum, Inc. to Participate in Barnett Shale Drilling Program
LAS VEGAS, Oct 26, 2005 (BUSINESS WIRE) -- KOKO Petroleum, Inc. (PINK SHEETS: KKPT) announced today that it has taken a minority participation working interest in the Boyd No. 1 well in the Barnett Shale play, north of Fort Worth, Texas. This well is the first in a planned program to exploit oil and gas reserves from leasehold interests held in the Barnett Shale play located in Cooke, Wise and Montague Counties, Texas.
The Barnett Shale is the largest natural gas play in Texas. It is presently producing 900 MMCF of gas per day and is considered one of the largest U.S. domestic natural gas plays with sizable, remaining resource potential. The first Barnett Shale wells were drilled and completed in the early 1980s by Mitchell Energy of Houston, Texas. According to an in-depth 2004 sector report on the Barnett Shale, developed by Morgan Stanley (NYSE:MWD), the Barnett Shale play is estimated to hold reserves in the non-core area that could be as high as 150 BCF per 1,000 acres. The report estimated that because of the amount of gas available in the area, successful wells in the Barnett Shale should be economically viable in almost any gas price environment. There are 75 rigs currently operating in the area.
Under the terms of the participation agreement with Rife Energy Operating, Inc. (the program's operator), KOKO Petroleum has acquired a minority working interest (approx. 10%) in the drilling and completion of one well (Boyd No. 1) that has already been drilled to an approximate depth of 8,800 feet. This well is now in the completion stage and is expected to go on-line in approximately 45 days. The total cost for drilling and completion of the McCoy No. 2 well is anticipated to be approximately $1.4 million.
"Petroleum and natural gas production in the Barnett Shale play has been increasing steadily year after year. This is by far one of the most active and prolific gas fields in America right now and as such is garnering a lot of attention all the way from the oil patch to Wall Street. The group that we have joined in this Barnett Shale drilling program is affiliated with one of the major stakeholders in the area with scores of wells already in production. We are very confident in their proven ability to locate the best drilling sites in the area and to efficiently tap the vast gas resources held in Barnett Shale. This project is one of several next steps in KOKO Petroleum's ongoing program to build a diverse portfolio of promising oil and gas properties and prospects. We plan to continue pursuing other promising prospects that should help us build a diverse portfolio with long-term value for our shareholders," says Mr. Ted Kozub, Chief Executive Officer of KOKO Petroleum, Inc.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications which may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above.
SOURCE: KOKO Petroleum, Inc.
CONTACT: KOKO Petroleum, Inc.
Investor Relations:
Andrea Bleasdale, 888-740-7276
www.kokooil.com
Copyright Business Wire 2005
Welcome back :)
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Big stuff brewing here
AMAR -- Amarillo Biosciences, Inc.
Com (1 Cent)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Amarillo Biosciences Licenses Low Dose Oral Interferon to Global Kinetics for Sale in Three Countries in SE Asia
Avian Flu Fuels Interest in Low Dose Oral Interferon as Potential Therapy
AMARILLO, TX, Oct 20, 2005 (MARKET WIRE via COMTEX) -- Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had entered into a licensing and supply agreement with Seattle-based Global Kinetics, Inc. to provide low dose oral interferon for sale in Cambodia, Laos and Vietnam.
Interest in the Company's low dose oral interferon has risen with international concern about the potential of the current bird flu outbreak to develop into a pandemic. Health care professionals agree that the public is vulnerable to the pending influenza pandemic. Effective vaccination for influenza is the goal of health officials. However, no vaccine is yet available for the H5N1 virus (bird flu), and the therapies that do exist, such as Tamiflu, are in limited supply worldwide. Consequently, ABI and Global Kinetics are working together to bring a promising new prevention and treatment option for influenza to the developing world.
Global Kinetics (www.globalkinetics.net) intends to market ABI's low dose oral interferon through a Cambodian company (Global Kinetics of Cambodia). "Low-dose oral interferon represents an inexpensive, non-toxic modulation of the immune system during, or before, influenza infection. Our first purchase order is expected from the Kingdom of Cambodia so a supply of oral interferon will be available in case bird flu infects government personnel. Government officials in Cambodia have reviewed the clinical observations made on thousands of influenza patients in the former Soviet Union, Bulgaria, China, and Japan. These studies indicate that significant clinical benefits occurred in patients given low-dose interferon intranasally or orally during natural outbreaks of influenza," said Global Kinetics President Jerry Frasier. ABI President Joseph Cummins said, "We are pleased to be working with Global Kinetics and look forward to a long lasting and mutually beneficial relationship."
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2004.
Investor Relations:
Philippe Niemetz
WPH Consultants, Ltd.
Tel: 800-477-7570
Tel: 212-344-6464
Fax: 212-618-1276
e-mail: Contact via http://www.marketwire.com/mw/emailprcntct?id=F69DBBFE40E22DF3
Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: 806-376-1741 x 13
Fax: 806-376-9301
e-mail: Contact via http://www.marketwire.com/mw/emailprcntct?id=2E4BF0BD1B550E06
SOURCE: Amarillo Biosciences, Inc.
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
AMAR -- Amarillo Biosciences, Inc.
Com (1 Cent)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Amarillo Biosciences Licenses Low Dose Oral Interferon to Global Kinetics for Sale in Three Countries in SE Asia
Avian Flu Fuels Interest in Low Dose Oral Interferon as Potential Therapy
AMARILLO, TX, Oct 20, 2005 (MARKET WIRE via COMTEX) -- Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had entered into a licensing and supply agreement with Seattle-based Global Kinetics, Inc. to provide low dose oral interferon for sale in Cambodia, Laos and Vietnam.
Interest in the Company's low dose oral interferon has risen with international concern about the potential of the current bird flu outbreak to develop into a pandemic. Health care professionals agree that the public is vulnerable to the pending influenza pandemic. Effective vaccination for influenza is the goal of health officials. However, no vaccine is yet available for the H5N1 virus (bird flu), and the therapies that do exist, such as Tamiflu, are in limited supply worldwide. Consequently, ABI and Global Kinetics are working together to bring a promising new prevention and treatment option for influenza to the developing world.
Global Kinetics (www.globalkinetics.net) intends to market ABI's low dose oral interferon through a Cambodian company (Global Kinetics of Cambodia). "Low-dose oral interferon represents an inexpensive, non-toxic modulation of the immune system during, or before, influenza infection. Our first purchase order is expected from the Kingdom of Cambodia so a supply of oral interferon will be available in case bird flu infects government personnel. Government officials in Cambodia have reviewed the clinical observations made on thousands of influenza patients in the former Soviet Union, Bulgaria, China, and Japan. These studies indicate that significant clinical benefits occurred in patients given low-dose interferon intranasally or orally during natural outbreaks of influenza," said Global Kinetics President Jerry Frasier. ABI President Joseph Cummins said, "We are pleased to be working with Global Kinetics and look forward to a long lasting and mutually beneficial relationship."
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2004.
Investor Relations:
Philippe Niemetz
WPH Consultants, Ltd.
Tel: 800-477-7570
Tel: 212-344-6464
Fax: 212-618-1276
e-mail: Contact via http://www.marketwire.com/mw/emailprcntct?id=F69DBBFE40E22DF3
Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: 806-376-1741 x 13
Fax: 806-376-9301
e-mail: Contact via http://www.marketwire.com/mw/emailprcntct?id=2E4BF0BD1B550E06
SOURCE: Amarillo Biosciences, Inc.
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Big story here long term. AMAR and CMBV :)
AMAR & CMBV - Bird Flu Deal
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
AMAR & CMBV - Bird Flu Deal
CMBV -- Cambodian Ventures Ltd.
Com
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Cambodian Ventures Limited Reaches Definitive Agreement to Acquire Interest in a Biomedical Company Specializing in Human Avian Influenza Solutions
LOWELL, MA AND PHNOM PENH, CAMBODIA AND MONTREAL, Nov 03, 2005 (MARKET WIRE via COMTEX) -- Cambodian Ventures Limited (OTC: CMBV), announced today that it has reached a definitive agreement to acquire up to 25% of Montreal based Canadian Bio Med Systems Inc.
CBMS will focus on providing education, preventive and protective products, as well as anti-influenza medications.
Canadian Bio Med Systems (CBMS) is a company recently formed to provide solutions to the general public in dealing with the containment of the deadly avian influenza A virus (H5N1), also known as "Bird Flu," among humans.
In conjunction with developing a consistent source of Tamiflu for use in the treatment of H5N1, the company is pursuing the evaluation of a treatment of Avian Flu through the use of low dose Oral Interferon, which is available for sale in Cambodia, Laos and Vietnam. Low dose Oral Interferon is manufactured by Amarillo Biosciences, Inc. and distributed in South East Asia by Global Kinetics of Cambodia.
CBMS's goal is to provide education and products to prevent the spread of Avian Flu, protect individuals who live or travel through areas of risk, and to provide available treatment modalities that are available in various countries that are affected.
Among the founders of CBMS is Dr. George Tsoukas, M.D., Endocrinologist, Associate Professor, McGill University Health Centre, Montreal, Quebec. Dr. Tsoukas has extensive experience in medical education and has produced and directed a popular television program explaining medical conditions to the public. Dr. Tsoukas was chief examiner for the Quebec College of Endocrinologists. He obtained his medical degree at McGill University and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.
Canadian Bio Med Systems web site www.canadianbiomed.com
Safe Harbor Statement: The statements, other than the statements of historical facts may be deemed to contain forward-looking statements with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and competition for the company's products and services, the availability to the company of adequate financing to support its anticipated activities, the ability of the company to generate cash flow from operations and the ability of the company to manage its operations.
CONTACT:
Cambodian Ventures Investor Relations
1-416-356-4737
www.cambodianventures.com
SOURCE: Cambodian Ventures Limited
CONTACT: http://www.cambodianventures.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
AMVS seems to be turning the cornger her as the next levels of resistance are .08 .11 .145 Looking for volume to continue into monday and early this week
http://stockhideout.com/pix/amvs1.png
SVNP was a stock we have had on and off during the past few months. Now showing some signs of life again with a mini cup to 1.45 1.58 then a 200 EMA break of 1.62 to really break out
http://stockhideout.com/pix/svnp1.png
CMBV I am holding still as we had a nice volume day on friday. This is not a stock you put in huge cash, but something you can put a small amount in and ride it out as the potential is there based on the latest PR for bird flu. Resistance is at .0033 .004 .006 .007 .011
http://stockhideout.com/pix/cmbv1.png
INSQ if it can hold .0027 it can test .0036 .004 .0048 .0056. If we dont hold .0027 range then next support is at .0023
http://stockhideout.com/pix/insq1.png
MOBL with resistance at .20 .21 .24 .25 .26 .32 as indicators turn up, might be a nice bottom around .18 .16 ranges
http://stockhideout.com/pix/mobl1.png
RYAN here looks to be finding a bottom at 10.00 range with resistance at 10.58 10.92 11.28 11.74 as indicators trend back up
http://stockhideout.com/pix/ryan.png
__________________
All my posts are opinions only. Please do not buy or sell on my recommendation only as I am not a registered broker.
Need a new broker? http://www.ocsecurities.com
Want a Stockhideout Shirt http://www.trader-tees.com/product_009.htm
For the fastest technical chart scanning service visit www.prochartscan.com
AMVS seems to be turning the cornger her as the next levels of resistance are .08 .11 .145 Looking for volume to continue into monday and early this week
http://stockhideout.com/pix/amvs1.png
SVNP was a stock we have had on and off during the past few months. Now showing some signs of life again with a mini cup to 1.45 1.58 then a 200 EMA break of 1.62 to really break out
http://stockhideout.com/pix/svnp1.png
CMBV I am holding still as we had a nice volume day on friday. This is not a stock you put in huge cash, but something you can put a small amount in and ride it out as the potential is there based on the latest PR for bird flu. Resistance is at .0033 .004 .006 .007 .011
http://stockhideout.com/pix/cmbv1.png
INSQ if it can hold .0027 it can test .0036 .004 .0048 .0056. If we dont hold .0027 range then next support is at .0023
http://stockhideout.com/pix/insq1.png
MOBL with resistance at .20 .21 .24 .25 .26 .32 as indicators turn up, might be a nice bottom around .18 .16 ranges
http://stockhideout.com/pix/mobl1.png
RYAN here looks to be finding a bottom at 10.00 range with resistance at 10.58 10.92 11.28 11.74 as indicators trend back up
http://stockhideout.com/pix/ryan.png
__________________
All my posts are opinions only. Please do not buy or sell on my recommendation only as I am not a registered broker.
Need a new broker? http://www.ocsecurities.com
Want a Stockhideout Shirt http://www.trader-tees.com/product_009.htm
For the fastest technical chart scanning service visit www.prochartscan.com
AMVS seems to be turning the cornger her as the next levels of resistance are .08 .11 .145 Looking for volume to continue into monday and early this week
http://stockhideout.com/pix/amvs1.png
SVNP was a stock we have had on and off during the past few months. Now showing some signs of life again with a mini cup to 1.45 1.58 then a 200 EMA break of 1.62 to really break out
http://stockhideout.com/pix/svnp1.png
CMBV I am holding still as we had a nice volume day on friday. This is not a stock you put in huge cash, but something you can put a small amount in and ride it out as the potential is there based on the latest PR for bird flu. Resistance is at .0033 .004 .006 .007 .011
http://stockhideout.com/pix/cmbv1.png
INSQ if it can hold .0027 it can test .0036 .004 .0048 .0056. If we dont hold .0027 range then next support is at .0023
http://stockhideout.com/pix/insq1.png
MOBL with resistance at .20 .21 .24 .25 .26 .32 as indicators turn up, might be a nice bottom around .18 .16 ranges
http://stockhideout.com/pix/mobl1.png
RYAN here looks to be finding a bottom at 10.00 range with resistance at 10.58 10.92 11.28 11.74 as indicators trend back up
http://stockhideout.com/pix/ryan.png
__________________
All my posts are opinions only. Please do not buy or sell on my recommendation only as I am not a registered broker.
Need a new broker? http://www.ocsecurities.com
Want a Stockhideout Shirt http://www.trader-tees.com/product_009.htm
For the fastest technical chart scanning service visit www.prochartscan.com
October 31st possible plays
--------------------------------------------------------------------------------
AMVS seems to be turning the cornger her as the next levels of resistance are .08 .11 .145 Looking for volume to continue into monday and early this week
http://stockhideout.com/pix/amvs1.png
SVNP was a stock we have had on and off during the past few months. Now showing some signs of life again with a mini cup to 1.45 1.58 then a 200 EMA break of 1.62 to really break out
http://stockhideout.com/pix/svnp1.png
CMBV I am holding still as we had a nice volume day on friday. This is not a stock you put in huge cash, but something you can put a small amount in and ride it out as the potential is there based on the latest PR for bird flu. Resistance is at .0033 .004 .006 .007 .011
http://stockhideout.com/pix/cmbv1.png
INSQ if it can hold .0027 it can test .0036 .004 .0048 .0056. If we dont hold .0027 range then next support is at .0023
http://stockhideout.com/pix/insq1.png
MOBL with resistance at .20 .21 .24 .25 .26 .32 as indicators turn up, might be a nice bottom around .18 .16 ranges
http://stockhideout.com/pix/mobl1.png
RYAN here looks to be finding a bottom at 10.00 range with resistance at 10.58 10.92 11.28 11.74 as indicators trend back up
http://stockhideout.com/pix/ryan.png
__________________
All my posts are opinions only. Please do not buy or sell on my recommendation only as I am not a registered broker.
October 31st possible plays
--------------------------------------------------------------------------------
AMVS seems to be turning the cornger her as the next levels of resistance are .08 .11 .145 Looking for volume to continue into monday and early this week
http://stockhideout.com/pix/amvs1.png
SVNP was a stock we have had on and off during the past few months. Now showing some signs of life again with a mini cup to 1.45 1.58 then a 200 EMA break of 1.62 to really break out
http://stockhideout.com/pix/svnp1.png
CMBV I am holding still as we had a nice volume day on friday. This is not a stock you put in huge cash, but something you can put a small amount in and ride it out as the potential is there based on the latest PR for bird flu. Resistance is at .0033 .004 .006 .007 .011
http://stockhideout.com/pix/cmbv1.png
INSQ if it can hold .0027 it can test .0036 .004 .0048 .0056. If we dont hold .0027 range then next support is at .0023
http://stockhideout.com/pix/insq1.png
MOBL with resistance at .20 .21 .24 .25 .26 .32 as indicators turn up, might be a nice bottom around .18 .16 ranges
http://stockhideout.com/pix/mobl1.png
RYAN here looks to be finding a bottom at 10.00 range with resistance at 10.58 10.92 11.28 11.74 as indicators trend back up
http://stockhideout.com/pix/ryan.png
__________________
All my posts are opinions only. Please do not buy or sell on my recommendation only as I am not a registered broker.
Looking good for more volume.
ACCUMULATION.....nice :)
Hoping for a better week :(
SVNP is going to focus on cell phone gaming :)
$$$$$
Bad news on the fax campaign??? Company looks solid though....we will have to see
More news here this week....good upside :)
Story keeps getting better :)
LLLI looks real good.....u long?
Still has good upside :)
CMBV. :)